Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis

JAMA Dermatology
Alison D TreisterPeter A Lio

Abstract

Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased incidence of conjunctivitis in patients who received dupilumab compared with those who received placebo. To describe the characteristics of patients who develop conjunctivitis secondary to dupilumab treatment for AD. Case series of 12 patients who reported development of conjunctivitis from a cohort of 142 patients treated with dupilumab for AD at a secondary care center from March 14, 2017, to March 29, 2018. Patients received a 600-mg injection of dupilumab as a loading dose and a 300-mg injection every 2 weeks thereafter. Primary outcome measures were severity of AD as measured by the Investigator Global Assessment (IGA) score, a 5-point scale from 0 (clear) to 4 (severe), at the time of dupilumab initiation and at conjunctivitis onset. Of the 12 patients included in this series, 7 (58%) were male. The mean (SD) age of patients was 30 (8.1) years at the time conjunctivitis developed. All patients showed improvement of their AD at the time of conjunctivitis diagnosis, with a mean (SD) 1.9 (0.8)-point decrease in IGA score and 47.8% (11.2%) decrease in body surface area affected. Nine of the 12 patients (75%) had severe baseline AD with an IGA s...Continue Reading

References

Oct 8, 2013·The Journal of Allergy and Clinical Immunology·Jonathan I Silverberg, Jon M Hanifin
Jul 2, 2015·Investigative Ophthalmology & Visual Science·Johanna Tukler HenrikssonStephen C Pflugfelder
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Jun 12, 2017·Journal of the American Academy of Dermatology·Jacob P ThyssenAlexander Egeberg
Nov 29, 2017·International Immunopharmacology·Zuzhen OuWeikang Zhou
Dec 21, 2017·American Journal of Ophthalmology Case Reports·Alexander C BarnesJulian D Perry

❮ Previous
Next ❯

Citations

Dec 19, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·U Blume-PeytaviT Nocera
Jan 24, 2019·Expert Opinion on Biological Therapy·Randall LiEmma Guttman-Yassky
Apr 18, 2019·JAMA Dermatology·Alison D TreisterPeter A Lio
Apr 18, 2019·JAMA Dermatology·Aleksi J Hendricks, Vivian Y Shi
Mar 10, 2019·The British Journal of Dermatology·B AkinladeA Wollenberg
Jun 21, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·J WohlrabA Wollenberg
May 31, 2019·Current Opinion in Allergy and Clinical Immunology·Jorien van der SchaftDeepak M W Balak
Sep 3, 2019·The British Journal of Dermatology·Chia-Yu Chu
Apr 9, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·C M OlesenT Agner
Feb 21, 2019·Human Vaccines & Immunotherapeutics·Quinn ThibodeauxTina Bhutani
Sep 8, 2020·Immunotherapy·Kayla FourzaliGil Yosipovitch
Aug 23, 2019·The British Journal of Dermatology·R A WaldmanS B Sloan
Nov 28, 2018·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Johannes WohlrabThomas Werfel
Jun 24, 2019·Ophthalmology and Therapy·Adrien MaudinetThi Ha Chau Tran
May 31, 2019·The British Journal of Dermatology·L E M de WijsD J Hijnen
Aug 4, 2020·Translational Vision Science & Technology·Brad P Barnett, Natalie A Afshari
Jan 1, 2020·The Journal of Dermatological Treatment·Debora H LeeJeremiah P Tao
Jul 4, 2020·Clinical Reviews in Allergy & Immunology·Peter Ip Fung Chun, Heather Lehman
Jul 29, 2019·American Journal of Clinical Dermatology·Kristen M BeckWilson Liao
Dec 20, 2019·The British Journal of Dermatology·M ArdeleanuN M H Graham
Dec 15, 2020·Dermatology and Therapy·Firas Constantin KreeshanHamish John Alexander Hunter
Oct 11, 2020·Journal of the American Academy of Dermatology·Maria C SchneeweissJoseph F Merola
May 23, 2020·The Ocular Surface·Canan Asli UtineEsen Akpek
Jan 23, 2021·American Journal of Clinical Dermatology·Ashish BansalMarius Ardeleanu
Mar 18, 2021·Journal of the American Academy of Dermatology·Yu Wang, Joseph L Jorizzo
Mar 21, 2021·The Journal of Dermatology·Satoshi TakeuchiMasutaka Furue
Mar 3, 2019·Journal of the American Academy of Dermatology·Sarah FaizUNKNOWN Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
Sep 22, 2020·Journal of the American Academy of Dermatology·Justine ChengMark A Greiner
May 14, 2021·International Medical Case Reports Journal·Urmi Mehta, Marjan Farid
Mar 4, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·G CalabreseG Argenziano
Jun 15, 2021·Journal of the American Academy of Dermatology·Shanthi NarlaEric L Simpson
Jan 8, 2020·International Journal of Women's Dermatology·Jodie RaffiJenny E Murase
Jun 11, 2019·Archivos de la Sociedad Española de Oftalmología·J Roca-GinésM Á Navarro-Mira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Related Papers

The Journal of Allergy and Clinical Immunology. in Practice
Andreas WollenbergM de Bruin-Weller
MMW Fortschritte der Medizin
D Reinhardt
The New England Journal of Medicine
Eric L SimpsonSOLO 1 and SOLO 2 Investigators
The New England Journal of Medicine
Eric L SimpsonMarius Ardeleanu
© 2022 Meta ULC. All rights reserved